Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
7.38
-0.50 (-6.35%)
Apr 9, 2026, 3:04 PM CST
Market Cap8.10B +14.9%
Revenue (ttm)578.61M -26.0%
Net Income83.77M +1.7%
EPS0.08 -2.5%
Shares Out1.03B
PE Ratio99.60
Forward PEn/a
Dividend0.02 (0.23%)
Ex-Dividend DateJul 4, 2025
Volume162,450,036
Average Volume82,024,660
Open8.64
Previous Close7.88
Day's Range7.37 - 8.64
52-Week Range5.47 - 9.40
Beta0.10
RSI60.38
Earnings DateApr 23, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen... [Read more]

Sector Healthcare
Founded 1994
Employees 889
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

Financial Statements